斯萊克(300382.SZ):第三期員工持股計劃出售完畢
格隆匯9月7日丨斯萊克(300382.SZ)公佈,公司第三期員工持股計劃所持有的公司股票共計115萬股,佔公司總股本的0.20%,已於2021年8月27日至2021年9月7日通過集中競價方式全部出售完畢。公司實施第三期員工持股計劃期間,嚴格遵守股票市場交易規則,遵守中國證監會、深圳證券交易所關於信息敏感期不得買賣股票的規定,不存在利用內幕信息進行交易的情形。
根據《深圳證券交易所上市公司信息披露指引第4號—員工持股計劃》等法律法規以及《斯萊克第三期員工持股計劃(草案)》的相關規定,公司本次員工持股計劃實施完畢並提前終止,後續將進行財產清算和分配工作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.